Multi-centre, randomized, double-blind, placebo-controlled, phase II study assessing in two sequential cohorts the safety, efficacy and tolerability of a 15 mg BID and a 30 mg BID doses of SER150TBS in well controlled type II diabetic patients with diabetic nephropathy and albuminuria in stable antidiabetic treatment
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2017
At a glance
- Drugs SER 150 (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Serodus
- 25 Jan 2017 Status changed from active, no longer recruiting to completed.
- 28 Nov 2016 According to a Serodus media release, last patient has been dosed with the last dose in cohort 2 and key results are expected during the first week of 2017.
- 28 Nov 2016 Status changed from recruiting to active, no longer recruiting, as per a Serodus media release.